Table 1 Key population and epidemiology inputs, MSM population
From: Investigating zero transmission of HIV in the MSM population: a UK modelling case study
Input | Value | Source |
|---|---|---|
Initial population, N | 621,210 | |
MSMLWH population, % (n) | 8.097 (50,299) | Public Health England 2020 [16] |
Undiagnosed MSMLWH, % (n) | 5.77 (2,902) | Public Health England 2020 [16] |
Diagnosed MSMLWH, % (n) | 94.23 (47,397) | Public Health England 2020 [16] |
PrEP users, % of HIV-negative population (n) | 4.326 (24,698) | Public Health England 2020, [16] Expert Opinion |
Efficacy of PrEP, % | 86.00 | Cambiano et al., 2018 [19] |
Treated population, % of diagnosed population (n) | 98.44 (46,658) | Public Health England, 2020 [16] |
MSMLWH who are virologically suppressed, % of treated population (n) | 97.00 (45,258) | Public Health England, 2020 [16] |
Initial health state distribution, undiagnosed population, % (n) | ||
CD4 > 500 | 45.80 (1,329) | Public Health England, 2020 [16] |
500 ≥ CD4 ≥ 350 | 19.06 (553) | Public Health England, 2020 [16] |
350 > CD4 > 200 | 1.04 (30) | Public Health England, 2020 [16] |
CD4 ≤ 200 | 34.10 (990) | Public Health England, 2020 [16] |
Initial health state distribution, not on treatment population, % (n) | ||
CD4 > 500 | 45.80 (339) | Public Health England, 2020 [16] |
500 ≥ CD4 ≥ 350 | 19.06 (141) | Public Health England, 2020 [16] |
350 > CD4 ≥ 200 | 1.04 (8) | Public Health England, 2020 [16] |
CD4 < 200 | 34.10 (252) | Public Health England, 2020 [16] |